Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

gitis.

About Keflex:

Keflex(R) (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at http://www.middlebrookpharma.com/products_antibiotics/keflex_antibiotics.aspx.

This announcement contains historical financial information as of and for three-month and twelve-month periods ended December 31, 2007 and December 31, 2006 that is unaudited, and MiddleBrook assumes no obligation to update this information based on new information or future performance except as may be specifically required by applicable law or regulation. The unaudited annual financial information is subject to audit by independent accountants on an annual basis following the close of each calendar year.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited t
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasdaq: PDL...7,2009astheex-dividenddateforits$200millionspecial...ontransactioncompletedonNovember2,2009.Thedividend...rdontherecorddate,December1,2009.NASDAQhassettheap...eofcommonstockforpurposesoftheex-dividenddateonNov...
(Date:11/23/2009)...DesignC or p.(IDC)announcedtodaythatDr.BruceL.A.Ca...uccessfultrackrec or dinbiotechnologyexecutivemana...Genetics,inSeattle,WAandChiefScientificOfficeratNo...://www.newscom.com/cgi-bin/prnh/20091123/SF15228 )...Officercommented,"IamdelightedtowelcomeDr.BruceCar...
(Date:11/23/2009)...all/--CornerstoneTherapeuticsInc.(Nasdaq: CRTX ),a...evelopingandcommercializingsignificantproductsprim...ncedthatCraigA.Collard,PresidentandChiefExecutiveO...AnnualPiperJaffrayHealthCareConferenceat3:30PMETon...ewYorkCity. ,, AliveaudioandarchivedwebcastofCo...
(Date:11/20/2009)...irstCall/ -- Dendreon Corporation (Nasdaq: DNDN )...istration (FDA) provided written acknowledgement t...ation (BLA) for PROVENGE® (sipuleucel-T) is a...iption Drug User Fee Act (PDUFA) date of May 1, 20...ended BLA. Dendreon is seeking licensure for PROV...
Breaking Biology Technology:PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3
...d, Ph.D., Joins as Chief Executive Officer, MENLO...y, Inc. (FAB), a privately held biotechnology comp...ies B financing. Prior investor SV Life,Sciences (...lta Partners.,The proceeds from the financing will...synthesis technology to produce biologic drugs and...
...urg Regional Education Consortium Promoting Advanc..., Dec. 7 High school and,college students from th...anced technology careers and curriculum through a ...s and the commonwealth., At BioTech Day 2007, hos...chnology, Community and Economic Development Deput...
...D, Calif., Dec. 7 Ardea Biosciences,Inc. (Nasdaq:...ief Executive,Officer, Barry D. Quart, PharmD, wil...eatment" panel discussion at the RBC Capital Marke...er 12, 2007 at 1:30 p.m. (ET) at,the Westin Times ...t of the,presentation and panel discussion will be...
Other Biology Technology:Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 2Fundamental Applied Biology, Inc. Completes $21 Million Series B Financing 3Capital Area Biotechnology Partnership Receives $160,000 State Investment 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 2Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference 3
(Date:11/23/2009)... available in German . , A bit of imaginati...be a bad thing. It could help to add data from are...ver, it must do so constructively. In order to inf...h more than just imagination, physicists at the Ma...d a theory of spatial perception called informatio...
(Date:11/22/2009)...ring South Korean scientists have succeeded in pro...ough bioengineering, rather than through the use o... research, which may now allow for the production ...d in two papers in the journal Biotechnology and ...sary. , Polymers are molecules found in everyda...
(Date:11/22/2009)...e Brain Research Centre, a partnership of the Univ... Vancouver Coastal Health Research Institute, have...which brain cells die following a stroke, as well ...ults of the study were recently published online i...brain cells continue to die even after blood flow ...
Breaking Biology News(10 mins):Visual assistance for cosmic blind spots 2Visual assistance for cosmic blind spots 3Visual assistance for cosmic blind spots 4Bioengineers succeed in producing plastic without the use of fossil fuels 2New understanding about mechanism for cell death after stroke leads to possible therapy 2KGI Establishes Post Baccalaureate Premedical Program 58514 1KGI Establishes Post Baccalaureate Premedical Program 58514 2Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 1Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 2Tianyin Pharmaceutical Co to Present at the Roth China Conference on October 14 at 12 3A30 pm ET 58511 3InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 1InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 2
...nywhere in the world soon could be made completely...rside geneticists, done in collaboration with scie...arch Institute in the Philippines. By gradually in...nce," a property that enables rice to survive extr...entially any variety of rice could be made to surv...
...fluenza vaccines may increase elderly patients, im... offering this vulnerable population additional pr...in the May 22 issue of Archives of Internal Medici...containing inactivated influenza virus have been a...ications, according to background information in t...
...f Minnesota researchers have discovered how a prev...r year in the United States overcomes the effects ...e of its chromosomes. , Candida albicans, a type...lly harmless. In otherwise healthy people, it can ...or thrush) that are easily treated. But in people ...
Other Biology News:Researchers develop flood-tolerant California rice 2Researchers develop flood-tolerant California rice 3High-dose flu vaccines appear to safely boost immunity in elderly 2U of M researchers discover genetic key to treating deadly fungal infections 2
ZOOM IPGRunner Mini-cell from Invitrogen
Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam
Agarose, Type C from Calbiochem
Assay Diluent from BD Biosciences Pharmingen
Biology Products: